Form D · Other Investment Fund

Wellington Biomedical Innovation II Access Offshore LP

New York, NY · CIK 0001940379

Offering snapshot reported Aug 8, 2022 · SEC filing

Reported sold: $1M
Investors reported: 2
Minimum accepted: $0
First sale: Jul 27, 2022

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Aug 8, 2022	Initial	$1,000,000	No comparison	2	SEC filing

Offering details

Securities: Pooled investment fund
Exemptions: 06b, 3C, 3C.7
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-455208

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Goldman Sachs & Co LLC	361

Source: Form D, filed Aug 8, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

Each card uses that adviser's latest imported filing. Filing dates can differ; these disclosures do not confirm a current relationship.

Matched by reported Form D file number

WELLINGTON BIOMEDICAL INNOVATION II ACCESS OFFSHORE LP

Investment adviser: GOLDMAN SACHS ASSET MANAGEMENT, L.P.

Gross asset value: $42.9M
Beneficial owners: 29
ADV minimum commitment: $0

Reported in Form ADV on Aug 21, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Service providers

Fund administrator SEI GLOBAL SERVICES, INC. OAKS, Pennsylvania, United States Investor statements: Yes (provided to all investors) Related to adviser: No Other funds reporting this name →

Auditor PRICEWATERHOUSECOOPERS LLP BOSTON, Massachusetts, United States Other funds reporting this name →

Custodian STATE STREET BANK AND TRUST COMPANY BOSTON, Massachusetts, United States Related to adviser: No Other funds reporting this name →

Marketer GOLDMAN SACHS & CO. LLC NEW YORK, New York, United States Related to adviser: Yes Other funds reporting this name →

Prime broker ABN AMRO SECURITIES (USA) LLC NEW BRUNSWICK, New Jersey, United States Other funds reporting this name →

Provider details

Annual audit: Yes
Prime brokers: Yes
Custodians: Yes
Administrator other than the adviser: Yes
External marketing: Yes

PRICEWATERHOUSECOOPERS LLP
PCAOB 238

STATE STREET BANK AND TRUST COMPANY
LEI 571474TGEMMWANRLN572

GOLDMAN SACHS & CO. LLC
CRD 361 · SEC 801-16048

ABN AMRO SECURITIES (USA) LLC
CRD 151796 · SEC 8-68398

Fund asset history · 4 annual observations

Scroll to see all columns →

Fiscal year	Gross assets	Beneficial owners	ADV filed
2022	$27,450,000	15	Mar 31, 2023
2023	$37,949,813	29	Mar 28, 2024
2024	$33,762,120	29	Mar 31, 2025
2025	$42,882,768	29	Mar 31, 2026

Filing source

Form ADV 2125383 · Aug 21, 2026 · Schedule D 7.B.(1), fund 805-3333629071

Reported by GOLDMAN SACHS ASSET MANAGEMENT, L.P. (CRD 107738).

Other-Than Anual Amendment For Registered Adviser.

Official IAPD profile (latest public filing). Historical values on this page come from the SEC/IAPD filing archive; the public profile may show a newer filing.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Ashish Dodia	Executive
Jody Flaws	Executive
Richard Ruffer	Executive
Na Wellington Biomedical Innovation Ii Access Advisors Llc	Executive

Issuer details

Industry: Pooled Investment Fund (See others in industry)

Address:

200 West Street
New York, NY, 10282-2198
Phone: 212-902-1000